The myxoma program results from two decades of oncolytic virus research in the laboratory of Professor Grant McFadden. Myxoma is a pox virus that is highly immunostimulatory, and is non-pathogenic in any organism outside of rabbits. The virus has a unique ability to be carried systemically by human leukocytes where it can then infect tumor cells. Programs are developing for hematology (myeloma and AML) and solid tumors.
OncoMyx Therapeutics targets hematologic and solid tumors with a unique oncolytic virus called myxoma (MYXV) and a novel patented systemic delivery approach.
Are you the next big thing?
We’re a team of VC/PE who are excited about innovative ideas in life sciences. Submit your proposal to us!